Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
To determine the safety and efficacy of administering filgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgrastim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.
Unresectable Locally Advanced NSCLC
DRUG: Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
To determine the safety and efficacy of administering pegfilgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgramstim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients., One year
To determine the frequency of dose reductions, dose delays, and dose omissions during chemoradiotherapy with filgrastim and consolidation therapy with pegfilgrastim., One year
To determine the safety and efficacy of administering filgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgrastim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.